MOLECULAR/CELLULAR PREDICTORS OF BREAST CANCER PROGNOSIS

本项目的目标是识别分子病变 与某些乳腺癌的侵袭性临床行为相关， 将这些分子学见解转化为预后指标。我们将 继续我们的多学科方法，以了解 患者之间的细胞生物学的根本差异， 恶性上皮及其反应性间质。三个项目将 专注于肿瘤细胞中的分子病变，而两个 项目将集中在基质上。项目1将评估 四种ETS相关转录因子的失调及其 与HER 2癌基因过度表达的关系。项目2将克隆 乳腺癌中三种新发现的扩增子的靶基因。的 下一个项目将评估乳腺癌分子细胞遗传学， 新开发的技术。转换为临床相关检测 将由免疫病理学核心负责， 发现的项目，以幻灯片为基础的分析使用档案石蜡- 包埋组织项目的额外支持将来自 组织累积的临床核心，生物统计学和数据库核心， 细胞生物学核心和管理核心。

The goals of this Program Project are to identify the molecular lesions associated with aggressive clinical behavior of some breast cancers and to translate these molecular insights into prognostic indicators. We will continue our multidisciplinary approach toward understanding the fundamental differences among patients in the cellular biology of the malignant epithelium and its reactive stroma. Three projects will concentrate on the molecular lesions in the tumor cells, while two projects will concentrate on the stroma. Project 1 will evaluate dysregulation of four ETS related transcription factors and their relationship to HER2 oncogene overexpression. Project 2 will clone the target genes of three newly identified amplicons in breast cancer. The next project will evaluate breast cancer molecular cytogenetics using newly developed technologies. Translation to clinically relevant assays will be the responsibility of the Immunopathology Core which will apply discoveries of the Projects to slide-based assays using archival paraffin- embedded tissues. Additional support for the Projects will come from a Clinical Core for tissue accrual, a Biostatistics and Database Core, a Cell Biology Core, and an Administrative Core.